Nuvalent’s stock jumps 22% after ESMO 2024 – what’s next for this biotech game-changer?
Nuvalent, Inc., a biopharmaceutical company specialising in targeted cancer therapies, has seen its stock price skyrocket following the release of compelling data from two clinical trials at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona. The company’s shares surged by more than 22%, driven by positive data on its novel cancer drugs, […]